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Hepatitis C Virus-Induced Changes in MicroRNA 107 (miRNA-107)
and miRNA-449a Modulate CCL2 by Targeting the Interleukin-6
Receptor Complex in Hepatitis
Nayan J. Sarma,a Venkataswarup Tiriveedhi,a Jeffrey S. Crippin,c William C. Chapman,a Thalachallour Mohanakumara,b

ABSTRACT

Hepatitis C virus (HCV)-mediated liver diseases are one of the major health issues in the United States and worldwide. HCV infection has been reported to modulate microRNAs (miRNAs) that control various cell surface receptors and gene-regulatory
complexes involved in hepatic inflammation and liver diseases. We report here that specific downregulation of miRNA-107 and
miRNA-449a following HCV infection in patients with HCV-mediated liver diseases modulates expression of CCL2, an inflammatory chemokine upregulated in patients with chronic liver diseases, by targeting components of the interleukin-6 receptor
(IL-6R) complex. Computational analysis for DNA-bound transcription factors in the CCL2 promoter identified adjacent binding sites
for CCAAT/CEBP␣, spleen focus-forming virus, proviral integration oncogene (SPI1/PU.1), and STAT3. We demonstrate that CEBP␣,
PU.1, and STAT3 interacted with each other physically to cooperatively bind to the promoter and activate CCL2 expression. Analysis of
IL-6R and JAK1 expression in HCV patients by quantitative PCR showed significant upregulation when there was impaired miRNA107 and miRNA-449a expression, along with upregulation of PU.1 and STAT3, but not CEBP␣. miRNA-449a and miRNA-107 target
expression of IL-6R and JAK1, respectively, in vitro and also inhibit IL-6 signaling and impair STAT3 activation in human hepatocytes.
Taken together, our results demonstrate a novel gene-regulatory mechanism in which HCV-induced changes in miRNAs (miRNA449a and miRNA-107) regulate CCL2 expression by activation of the IL-6-mediated signaling cascade, which we propose will result in
HCV-mediated induction of inflammatory responses and fibrosis.
IMPORTANCE

Hepatitis C virus (HCV)-induced hepatitis is a major health concern worldwide. HCV infection results in modulation of noncoding microRNAs affecting major cellular pathways, including inflammatory responses. In this study, we have identified a microRNA-regulated pathway for the chemokine CCL2 in HCV-induced hepatitis. Understanding microRNA-mediated transcriptional-regulatory pathways will result in development of noninvasive biomarkers for better disease prediction and development
of effective therapeutics.

H

epatitis C virus (HCV)-mediated liver diseases are major
health issues, with an estimated 300 million people worldwide and 4 million in the United States affected (1). Most often,
HCV infection leads to gradual development of fibrosis and cirrhosis— end-stage liver diseases—and poses significant risk for
developing hepatocellular carcinoma (HCC) (2).
CCL2, or monocyte chemotactic protein 1, is a cytokine (11
kDa) of the CC chemokine family secreted by a variety of cell
types, including fibroblasts; peripheral blood mononuclear cells;
monocytes; macrophages; and epithelial, endothelial, smooth
muscle, and dendritic and microglial cells (3–6). CCL2 is upregulated in patients with chronic liver diseases, such as alcoholic hepatitis, nonalcoholic steatohepatitis (NASH), and HCV infection,
which are accompanied by inflammation (7–9). In mice, removal
of the cytokine interleukin-6 (IL-6) and components of the IL-6
receptor (IL-6R) complex and STAT3 impairs CCL2 expression
(10). IL-6 transmits a signal through components of the IL-6R
complex, through dimerization of the ligand binding IL-6R and
non-ligand binding gp130 (11). Upon ligand binding, JAK1,
JAK2, and TYK2 are activated by phosphorylation, which in turn
phosphorylates gp130 (12). Phosphorylated gp130 provides a
docking site for the DNA binding STAT1 and STAT3 (12). The
STATs, including STAT3, are then phosphorylated by activated
JAKs in the receptor complex, leading to dimerization, followed
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by nuclear translocation and activation of target genes (12, 13).
The DNA binding transcription factor proviral integration oncogene (SPI1/PU.1) regulates gene expression during hematopoietic
differentiation and development, and its knockdown results in the
absence of B-lymphoid and myeloid lineage cells (14). PU.1 is
required for the development and maintenance of lymphoid and
myeloid lineages of fetal liver hematopoietic stem cells (15). The
homodimeric DNA binding bZIP transcription factor CCAAT/
CEBP␣ controls cell proliferation and differentiation (16). In a
subset of patients diagnosed with HCC, CEBP␣ is upregulated and
controls the expression of genes, including hepatocyte-specific
microRNA-122 (miRNA-122), involved in hepatocarcinogenesis
(17, 18).
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MATERIALS AND METHODS
Patients. Liver biopsy specimens were obtained from 10 healthy-donor
livers (control), 10 alcoholic-hepatitis patients, 10 NASH patients, and 10
chronic-HCV patients (see Table S1 in the supplemental material). Patients with HIV and/or hepatitis B virus infection were not included in this
study. The collection of human samples and the studies were approved by
the Human Research Protection Committee at Washington University
(protocol 201104075), and the patients were enrolled after obtaining written informed consent.
Plasmids and siRNA constructs. For the reporter constructs, the
CCL2 promoter regions were amplified from human genomic DNA (Zyagen, CA) by PCR using iProof High-Fidelity DNA Polymerase (Bio-Rad,
CA). The PCR products were subcloned into the pGL4.11 vector (Promega, WI) upstream of a luciferase gene using the KpnI/EcoRV restriction
sites. Mutation in the STAT3 binding site in the base pair (bp) ⫺300
reporter construct was carried out using PCR. pCMV-XL4-PU.1
(SC315715) and pCMV-XL4-STAT3 (SC124165), Hsa-miRNA-449a
(SC400399), Hsa-miRNA-107 (SC400023), and controls were obtained
from Origene, MD. The construction of pcDNA-CEBP␣ is described elsewhere (23). Small interfering RNAs (siRNAs) specific for PU.1 (sc-36330),
STAT3 (sc-29493), CEBP␣ (sc-37047), IL-6R (sc-35663), JAK1 (sc35719), and a control (sc-37007) were purchased from Santa Cruz Biotechnology, CA. 3=-untranslated-region (UTR) clones of IL-6R
(HmiT009673-MT01) and JAK1 (HmiT009849-MT01) were purchased
from Genecopoeia, MD. Computational analysis to identify promoterbound transcription factors was done using the Transcription Element
Search System (TESS) (http://www.cbil.upenn.edu/cgi-bin/tess/tess).
miRNA target gene analysis was done using the website http://www
.targetscan.org.
miRNA and mRNA expression analysis. Total RNA was isolated from
the human hepatocytes or liver biopsy specimens using the RNA aqueous
kit (Ambion, NY). miRNA-449a and miRNA-107 levels were determined
using TaqMan miRNA assays and TaqMan Universal Master Mix-II (Life
Technologies, NY) with predesigned primers. Quantitative PCR (qPCR)
to analyze CCL2, PU.1, STAT3, CEBP␣, JAK1, and IL-6R was performed as
described previously (23). Each TaqMan assay was run in triplicate. The
⌬⌬CT values were calculated by normalizing the threshold cycle (CT) values
with GAPDH (glyceraldehyde-3-phosphate dehydrogenase gene) or RNU6B
expression and the respective gene expression in control samples.
Primary hepatocytes and HEPG2 cell line transfection. Primary human hepatocytes (Life Technologies) and HEPG2 (ATCC) cells were
grown and gene/siRNA transfections were carried out as described previously (23). The cytokine IL-6 (50 ng/ml; Sigma, MO) was added for 6 h
wherever indicated. The optimal amount of IL-6 required for induction
was determined by dose-dependent analyses. The knockdown efficiency
was measured by qPCR.
Immunofluorescence microscopy and Western blotting. For localization of PU.1, STAT3, and CEBP␣, 50,000 HEPG2 cells were grown on
coverslips in 24-well plates. Immunostaining was done as described previously (23). The antibodies (Abs) used for Western blotting and immunofluorescence were goat anti-CCL2 (sc-1304), mouse anti-JAK1 (sc376996), rabbit anti-IL-6R (sc-661), mouse anti-pSTAT3 (sc-8059), goat
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anti-CEBP␣ (sc-9315), and rabbit anti-PU.1 (sc-352). Fluorescein isothiocyanate (FITC)-conjugated rabbit anti-mouse IgG (sc-358916), rhodamine-conjugated rabbit anti-goat IgG (sc-3945), FITC-conjugated goat
anti-rabbit IgG (sc-2012), rhodamine-conjugated goat anti-mouse IgG
(sc-2092), FITC-conjugated mouse anti-rabbit IgG (sc-2359), and rhodamine-conjugated mouse anti-goat IgG (sc-2490) were used as secondary
reagents to demonstrate specific binding. The images were captured using
an Eclipse 80i fluorescence microscope (Nikon, NY) and processed using
Metamorph version 6.3r2 software (Molecular Devices, CA).
Luciferase reporter assay. Hepatocytes (1 ⫻ 105) were transfected in
24-well plates as described previously (23) with 1 g pGL4.11 luciferase
reporter vector driven by the CCL2 promoters, along with 2 g control
vector or vector expressing miRNA-449a, miRNA-107, PU.1, STAT3, or
CEBP␣ or 80 pmol of either control siRNA or siRNA specific for IL-6R,
JAK1, PU.1, STAT3, or CEBP␣. To control for efficiency of transfection,
0.1 g of pRL-TK (Promega, WI), which expresses Renilla luciferase, was
included. For miRNA target analysis, hepatocytes were transfected with 2
g of a luciferase reporter construct containing IL-6R 3= UTR or JAK1 3=
UTR, along with either control vector or vector expressing miRNA-449a
or miRNA-107. Luciferase activity was measured 48 h after transfection
using the Dual Luciferase Reporter Assay System (Promega, WI), and the
results were normalized to Renilla luciferase.
Coimmunoprecipitation. For immunoprecipitation of PU.1 with
CEBP␣, of PU.1 with pSTAT3, or of pSTAT3 with CEBP␣, IL-6-treated
hepatocytes (1 ⫻ 106) were used as described by Sarma and Yaseen (24).
One microgram of normal goat IgG, normal mouse IgG, goat antiCEBP␣, or mouse anti-pSTAT3 was used to immunoprecipitate the protein complexes. PU.1 or pSTAT3 was detected with rabbit anti-PU.1 or
mouse anti-pSTAT3, respectively.
ChIP. Chromatin immunoprecipitation (ChIP) was carried out with
ChIP-IT Express (Active Motif, CA) according to the manufacturer’s instructions, as described previously (23). One microgram of Abs for control IgG, PU.1, pSTAT3, or CEBP␣ was used to immunoprecipitate DNAprotein complexes. CCL2 promoter regions were amplified using PCR
and resolved on 2% agarose gels. The images were acquired with the
Chemidoc XRS System (Bio-Rad).

RESULTS

Specific downregulation of miRNA-107 and miRNA-449a and
upregulation of CCL2 in HCV livers with fibrosis. We previously
reported differential modulation of miRNAs, including miRNA107 and miRNA-449a, in HCV patients (23, 25). To determine the
expression levels of miRNA-107 and miRNA-449a following HCV
infection, biopsy specimens were collected from 10 normal livers
from cadaveric donors, 10 alcoholic-hepatitis patients, 10 NASH
patients, and 10 chronic-HCV patients. Expression analysis using
qPCR demonstrated that miRNA-107 is specifically downregulated by more than 2-fold (2.2-fold) in HCV-infected patients
(Fig. 1A). In contrast, no significant difference in the expression of
miRNA-107 was observed in alcoholic-hepatitis, NASH, and normal livers. Similarly, expression of miRNA-449a was also found to
be specifically downregulated more than 2-fold (2.8-fold) only in
the HCV-infected livers, but not in other disease conditions (Fig.
1B). RNU6B was used as the internal control.
Expression analysis showed upregulation of CCL2 in alcoholic
hepatitis (6.2-fold), NASH (5.8-fold), and HCV (10.0-fold) compared to normal livers (Fig. 1C). Expression of CCL2 in HCV
livers was significantly higher than in those of patients with alcoholic hepatitis and NASH (P ⬍ 0.001).
IL-6 regulates CCL2 activation through the IL-6R complex.
Components of the IL-6R complex were shown to be essential for
CCL2 expression (10). To determine the role of IL-6 in CCL2
expression, the reporter construct containing the ⫺2,000-bp re-
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In recent years, miRNAs have been shown to play an important
role in immune evasion, allograft rejection, cell cycle regulation,
and cancer progression (19–21). HCV infection has been shown
to result in aberrant miRNA expression that regulates HCV particle entry, propagation, and gene expression mechanisms, thus
playing a pivotal role in host immune evasion and inflammatory
responses (22, 23). In this report, we demonstrate that HCV-mediated regulation of miRNA-449a and miRNA-107 results in upregulation of CCL2 and modulates components of the IL-6R complex, which we propose will result in HCV-mediated induction of
inflammatory responses and fibrosis.

MicroRNA-Mediated Changes in HCV-Induced Inﬂammation

collected from 10 chronic-HCV patients, 10 alcoholic-hepatitis patients, 10 NASH patients, and 10 healthy-donor livers (control). Expression of miRNA-107
(A), miRNA-449a (B), and CCL2 (C) was determined by qPCR. The ⌬⌬CT values were calculated by normalizing the CT values with RNU6B or GAPDH and
miRNA-107 (A), miRNA-449a (B), or CCL2 (C) levels in controls. *, P ⬍ 0.05; two-tailed t test. The error bars represent standard deviations (SD) obtained from
three independent replicates.

gion of the human CCL2 promoter was transfected into human
hepatocytes and treated or not with IL-6, and luciferase activity
was measured. More than a 4-fold (4.7-fold) increase in the CCL2
reporter activity was observed in IL-6-treated cells compared to
the untreated cells, which was further confirmed by immunoblotting (Fig. 2A). This strongly suggests that IL-6 activates CCL2
through modulation of upstream transcription factors. Further,
knockdown of the IL-6 cell surface receptor gene, IL-6R, resulted
in a 2-fold decrease in IL-6-mediated CCL2 activation and protein
expression compared to controls (Fig. 2A). Knockdown of JAK1
also resulted in significant impairment (1.8-fold) of IL-6-mediated CCL2 reporter activity and protein expression (Fig. 2B).
Quantitative gene expression analysis showed 88% and 86%
knockdown of IL-6R and JAK1, respectively, in siRNA-treated
cells (see Fig. S1 in the supplemental material).
Identification of putative DNA binding transcription factors
in the CCL2 promoter regions. To identify DNA binding transcription factors that regulate the expression of CCL2, a computational analysis of ⫺2,000 bp of the promoter region was
performed using TESS. This bioinformatics analysis identified
two putative DNA binding sites for CEBP␣ (GCAAT), four
sites for PU.1 (GAGGAA), and one site for STAT3 (TTCCTG
GAA) at the bp ⫺138 position (Fig. 3A) in close proximity to
each other, suggesting that these three transcription factors
may be part of a transcriptional-regulatory complex that mediates CCL2 expression.
To demonstrate that these transcription factors regulate CCL2
expression, human hepatocytes were transfected with the CCL2
reporter construct, along with either empty vector or vector expressing PU.1, STAT3, or CEBP␣, and treated with IL-6 (Fig. 3B).
A significant increase in reporter activity was observed compared
to the empty vector with overexpression of PU.1 (3.3-fold),
STAT3 (7.0-fold), and CEBP␣ (5.4-fold) (Fig. 3B). To determine
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whether these transcription factors cooperate in activating CCL2, two
of the transcription factors (PU.1/STAT3, PU.1/CEBP␣, or STAT3/
CEBP␣) were cotransfected into hepatocytes, along with the CCL2
reporter construct. Cotransfection resulted in a significant increase in
reporter activity compared to either factor alone, suggesting cooperation between the factors in regulating CCL2 expression (Fig. 3B,
top). Overexpression of the transcription factors in the hepatocytes was confirmed by immunoblotting (Fig. 3B).
To further demonstrate that these transcription factors are required for IL-6-mediated expression of CCL2, human hepatocytes
were transfected with the CCL2 reporter construct, along with
either control siRNAs or siRNAs specific for PU.1, STAT3, or
CEBP␣, and treated with IL-6. Knockdown of PU.1 resulted in
28%, that of STAT3 resulted in 37%, and that of CEBP␣ resulted
in 25% decrease in the CCL2 reporter activity compared to the
control (Fig. 3C). Knockdown of any two transcription factors
(PU.1/STAT3, PU.1/CEBP␣, or STAT3/CEBP␣) resulted in a
significant decrease in reporter activity compared to knockdown of either factor alone, suggesting cooperation between
these factors in the transcriptional activation of CCL2 (Fig.
3C). Quantitative gene expression analysis showed 77%, 73%,
and 75% knockdown of PU.1, STAT3, and CEBP␣ in siRNAtreated cells (see Fig. S1 in the supplemental material). However, coexpression or coknockdown of PU.1, STAT3, and
CEBP␣ together impaired cell viability.
To determine whether the transcription factor binding sites are
essential, deletion mutants were designed based on the locations
of the DNA binding sites for CEBP␣, PU.1, and STAT3 on the
CCL2 promoter. These deletion mutants (Fig. 3D, black bars)
were introduced into hepatocytes, treated or not with IL-6, and
the luciferase activity was measured. Sequential deletion of the
CCL2 promoter impaired IL-6-mediated transcriptional induction compared to the bp ⫺2000 promoter (Fig. 3D). No signifi-
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FIG 1 miRNA-107 and miRNA-449a are downregulated and CCL2 is upregulated in HCV patients with fibrosis. RNA was isolated from liver biopsy specimens

Sarma et al.

cant differences in reporter activity were observed in untreated
cells, indicating that IL-6 is required for transcriptional regulators
to activate CCL2 (Fig. 3D). For reporter constructs (bp ⫺2000,
⫺800, and ⫺300), IL-6 treatment resulted in more than 2.5-fold
increase in reporter activity compared to untreated constructs.
However, a point mutation in the STAT3 binding site on the CCL2
promoter completely abolished the IL-6 response (Fig. 3D). This
indicates that STAT3, along with CEBP␣ and PU.1, plays a major
role in IL-6-mediated CCL2 induction.
CEBP␣, PU.1, and STAT3 form a transcriptional-activation
complex and bind to the CCL2 promoter. To determine whether
CEBP␣, PU.1, and STAT3 bind to adjacent DNA binding sites on
the CCL2 promoter, DNA-protein complexes from IL-6-treated
hepatocytes were immunoprecipitated with anti-CEBP␣,r antiPU.1, anti-STAT3, or control IgGs. ChIP and PCR using primers
specific for CCL2 promoter regions (Fig. 4A, black bars) demonstrated that CEBP␣, PU.1, and STAT3 bind to the promoter (Fig.
4B). CEBP␣ binds strongly to the ⫺800/⫺1200 and ⫺400/⫺800
regions and weakly to the ⫺1/⫺400 region; PU.1 binds strongly to
the ⫺800/⫺1200 and ⫺1/⫺400 regions and weakly to the ⫺400/
⫺800 region of the CCL2 promoter. The observed binding of
CEBP␣ in the ⫺800/⫺1200 region is likely due to the presence of
binding sites within ⫾250 bp of the PCR amplicon. The DNA
binding pattern of CEBP␣ and PU.1 strongly correlates with the
locations of the consensus binding sites on the CCL2 promoter.
STAT3 binds strongly to the ⫺1/⫺400 region, encompassing the
binding site (bp ⫺138). ChIP with the control IgGs did not enrich
CCL2 promoter regions, demonstrating the specificity for these
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transcription factors. No binding was observed in PCRs carried
out with primers specific for the ⫺300/⫺700 region of the ACTIN
(ACTA1) promoter that lacks these binding sites (Fig. 4B).
To demonstrate that these transcription factors are interdependent, human hepatocytes were transfected with either control
siRNA or siRNA specific for STAT3 and treated with IL-6, and
ChIP was carried out with either control IgG or anti-PU. Knockdown
of STAT3 impaired PU.1 DNA binding to its consensus site in the
CCL2 promoter (Fig. 4D). PU.1 binding to the ⫺800/⫺1200 and
⫺1/⫺400 regions in the STAT3 knockout cells was weaker than to the
cells with nonspecific siRNA. No DNA binding was observed in the
⫺400/⫺800 region in the STAT3 knockout cells.
To determine that CEBP␣, PU.1, and STAT3 form a transcriptional-regulatory complex, lysates from IL-6-treated hepatocytes
were subjected to immunoprecipitation with either isotype control IgG, anti-CEBP␣, or anti-STAT3, followed by immunoblotting with anti-PU.1 or anti-STAT3. Both PU.1 and STAT3 were
coimmunoprecipitated with endogenous CEBP␣, whereas no
binding was observed with the control IgG (Fig. 4D, left). PU.1
was coimmunoprecipitated with endogenous STAT3, and no
binding was observed with the control IgG (Fig. 4D, right).
To further define the interaction between CEBP␣, PU.1, and
STAT3, HEPG2 cells were treated with IL-6 and coimmunostained with anti-STAT3/anti-CEBP␣, anti-PU.1/anti-STAT3, or
anti-PU.1/anti-CEBP␣. All three transcription factors primarily
colocalized to the nucleus (Fig. 4E; for high-resolution images and
controls, see Fig. S2 and S3 in the supplemental material). The
nuclear colocalization of STAT3 with CEBP␣ (Fig. 4E, top), PU.1
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FIG 2 IL-6 regulates CCL2 activation through the IL-6 receptor complex components IL-6R and JAK1. (A) (Top) Hepatocytes were transfected with a reporter
construct driven by ⫺2,000 bp of the CCL2 promoter with (⫹) or without (⫺) IL-6 and nonspecific (control) siRNA or siRNAs specific for IL-6R. Firefly
luciferase activity in the cells was measured 48 h after transfection and normalized to a Renilla luciferase internal control. The numbers represent the fold change
over the untreated control (average of three independent replicates); the error bars represent SD. *, P ⬍ 0.05; two-tailed t test. (Bottom) The hepatocytes were
immunoblotted with anti-CCL2. Actin was used as the loading control. (B) (Top) Hepatocytes were transfected with the CCL2 reporter construct with either
nonspecific (control) siRNA or siRNAs specific for JAK1. The cells were treated with IL-6, and luciferase activity was measured as described for panel A. (Bottom)
The hepatocytes were immunoblotted with anti-CCL2 and anti-actin.

MicroRNA-Mediated Changes in HCV-Induced Inﬂammation

in the CCL2 promoter identified by computational analysis of ⫺2,000 bp upstream of the open reading frame using TESS. The vertical bars represent the
predicted consensus binding sites in the DNA for transcription factors CEBP␣, PU.1, and STAT3. (B) (Top) Hepatocytes were transfected with the ⫺2,000-bp
CCL2 promoter-driven luciferase construct, in addition to a control vector or vectors expressing CEBP␣, PU.1, and STAT3 or any two of these factors. Luciferase
activity was measured as described for Fig. 2A. (Bottom) Overexpression of CEBP␣, PU.1, or STAT3 was verified by immunoblotting with anti-CEBP␣,
anti-PU.1, or anti-STAT3. (C) Hepatocytes were transfected with the CCL2 promoter-driven luciferase construct, in addition to either nonspecific (control)
siRNA or siRNAs specific for CEBP␣, PU.1, STAT3, or any two of these factors. Luciferase activity was measured as described for Fig. 2A. *, P value obtained by
a two-tailed t test between the control and the individual transcription factors; **, P value between cotransfected transcription factors and either factor alone. (D)
Essential regions in the CCL2 promoter required for IL-6-mediated expression. Hepatocytes were transfected with luciferase reporters driven by deletion
constructs of CCL2 promoter constructs (bp ⫺2000, ⫺8000, ⫺300, or ⫺300 with STAT3 binding site mutated [*]) (black bars) with (⫹) or without (⫺) IL-6.
Luciferase activity was measured as described for Fig. 2A. *, P value obtained by a two-tailed t test between conditions with or without IL-6.

with STAT3 (4E, middle), and PU.1 with CEBP␣ (4E, bottom)
and coimmunoprecipitation (Fig. 4D) demonstrate that these
transcription factors physically interact and are part of a larger
transcription-regulatory complex.
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miRNA-449a and miRNA-107 regulate IL-6-mediated CCL2
expression and STAT3 phosphorylation by targeting IL-6R and
JAK1. To define the role of STAT3 in IL-6-mediated CCL2 expression, IL-6R or JAK1 knockout hepatocytes were treated or not
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FIG 3 Transcription factors CEBP␣, PU.1, and STAT3 cooperate to regulate CCL2 expression. (A) Schematic representation of transcription factor binding sites
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FIG 4 CEBP␣, PU.1, and STAT3 interact to bind to the CCL2 promoter. (A) Schematic representation of the CCL2 promoter showing binding sites for CEBP␣,
PU.1, and STAT3. The black horizontal bars represent regions specific for the PCR primers. (B) ChIP showing transcription factors binding to the CCL2
promoter. DNA-protein complexes were immunoprecipitated with anti-CEBP␣, anti-PU.1, anti-STAT3, or isotype control IgG from hepatocytes. Specific CCL2
promoter regions (shown in panel A) were detected by PCR. The top four rows (CEBP␣, PU.1, STAT3, IgG) represent immunoprecipitated chromatin, and the
bottom row represents total chromatin (Input). ACTIN promoter amplification is shown as the negative control. (C) STAT3 is required for PU.1 binding to the
CCL2 promoter. Hepatocytes were transfected with either nonspecific (control) siRNA or siRNAs specific for STAT3. DNA-protein complexes were immunoprecipitated with anti-PU.1. The top row represents CCL2 promoter regions immunoprecipitated by anti-PU.1 in hepatocytes transfected with nonspecific
siRNA, the middle row represents hepatocytes transfected with siRNAs specific for STAT3, and the bottom row shows input chromatin (Input). (D) Coimmunoprecipitation showing interaction between CEBP␣, PU.1, and STAT3 in hepatocytes. Whole-cell lysates (Input) from IL-6-treated hepatocytes were subjected
to immunoprecipitation with either isotype control IgG, anti-CEBP␣, or anti-STAT3, and the immunoprecipitated complexes (IP) were detected by immunoblotting with anti-PU.1 or anti-STAT3. (E) Nuclear colocalization of CEBP␣, PU.1, and STAT3. HEPG2 cells were treated with IL-6 and coimmunostained with
anti-STAT3/anti-CEBP␣ (top row), anti-PU.1/anti-STAT3 (middle row), or anti PU.1/anti-CEBP␣ (bottom row).

3738

jvi.asm.org

Journal of Virology

MicroRNA-Mediated Changes in HCV-Induced Inﬂammation

transfected with either nonspecific (control) siRNA or siRNAs specific for IL-6R (left) or JAK1 (right) and treated (⫹) or not (⫺) with IL-6. Phosphorylated
STAT3 was detected by immunoblotting with anti-pSTAT3. (B) Hepatocytes were transfected with a CCL2 luciferase reporter construct, in addition to the
control vector or vector expressing miRNA-449a, miRNA-107, or both. The cells were treated (⫹) or not (⫺) with IL-6, and luciferase activity was measured as
described for Fig. 2A. (C and D) Detection of CCL2, pSTAT3, and actin in hepatocytes from panel A using anti-CCL2, anti-pSTAT3, or anti-actin.

with IL-6 and subjected to immunoblotting using anti-pSTAT3,
which is specific for the phosphorylated form of STAT3. IL-6
treatment resulted in increased accumulation of phosphorylated
STAT3, and knockdown of IL-6R and JAK1 resulted in impairment of IL-6-mediated STAT3 phosphorylation (Fig. 5A).
To test whether HCV-mediated upregulation of CCL2 is regulated by miRNAs, human hepatocytes were transfected with the
CCL2 reporter construct, along with a control vector or vector
expressing miRNA-449a and/or miRNA-107, and treated or not
with IL-6. Expression of either miRNA-449a or miRNA-107 resulted in significant impairment (⬎2.5-fold) of IL-6-mediated expression of CCL2 (Fig. 5B). Expression of both miRNA-449a and
miRNA-107 resulted in further impairment (6.1-fold) of CCL2
activation compared to either miRNA alone, indicating cooperation between the two miRNAs (Fig. 5B). Expression of either of
these miRNAs also resulted in decreased CCL2 protein and
STAT3 phosphorylation (Fig. 5C), which was further accentuated
by expression of both miRNAs together, indicating cooperation in
mediating transcriptional signaling (Fig. 5D).
Computational target prediction of miRNA-449a and miRNA107 using Targetscan identified the 3=-UTR regions of IL-6R and
JAK1, respectively, as putative targets for translational silencing
(Fig. 6A and E). To test the specificity of these miRNAs, hepatocytes were transfected with a luciferase reporter containing the
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3=-UTR region of IL-6R or JAK1, along with either control vector
or vector expressing miRNA-449a or miRNA-107, and luciferase
activity was measured. Expression of miRNA-449a and miRNA107 resulted in significant reduction in the IL-6R (3.8-fold) and
JAK1 (3-fold) UTR reporter activity, indicating direct interaction
between the miRNAs and the 3=-UTR regions (Fig. 6B and F). To
further demonstrate that these miRNAs impair gene expression,
hepatocytes were transfected with either control vector or vector
expressing miRNA-449a or miRNA-107, and expression of IL-6R
and/or JAK1 was determined by qPCR and immunoblotting. Increased expression of miRNA-449a or miRNA-107 resulted in
more than 2-fold downregulation of IL-6R (55%) and JAK1
(67%) RNA and protein levels (Fig. 6C, D, G, and H).
IL-6R, JAK1, PU.1, and STAT3 are upregulated in HCV patients. To determine whether downregulation of miRNA-449a
and miRNA-107 in HCV livers is accompanied by upregulation of
their respective targets, IL-6R and JAK1, RNA was isolated from
10 normal, 10 alcoholic-hepatitis, 10 NASH, and 10 chronic-HCV
livers. qPCR analysis showed that IL-6R and JAK1 are upregulated
more than 2-fold (2.7- and 2.2-fold, respectively) in HCV livers
(Fig. 7A and B). In contrast, no significant difference in the expression of IL-6R and JAK1 was noted in alcoholic-hepatitis,
NASH, and normal livers. These results, along with our results
from in vitro studies using human hepatocytes, clearly indicate
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FIG 5 miRNA-449a and miRNA-107 regulate IL-6-mediated CCL2 expression and STAT3 phosphorylation by targeting IL-6R and JAK. (A) Hepatocytes were
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that upregulation of IL-6R, JAK1, and CCL2 (Fig. 1C) in HCV
livers can be attributed to downregulation of miRNA-449a and
miRNA-107.
Expression analysis of the transcription factors also showed
that PU.1 is upregulated (3.6-fold) only in HCV livers compared
to non-HCV and normal livers (Fig. 7C). However, expression of
STAT3 is upregulated 2.4-fold in alcoholic-hepatitis patients, 3.1fold in NASH patients, and 6.6-fold in HCV livers compared to
normal livers (Fig. 7D). We did not detect any differences in the
expression of CEBP␣ in any of these patient populations (Fig. 7E).
GAPDH was used as the internal control.
DISCUSSION

HCV infection has been shown to induce inflammatory cytokines/
chemokines, leading to activation of hepatic stellate cells (HSCs)
and development of fibrosis (26). We have previously identified
differential regulation of inflammatory cytokines, such as IL-17,
IL-1␤, IL-6, IL-8, monocyte chemoattractant protein 1 (MCP-1),
gamma interferon (IFN-␥), IL-4, IL-5, IL-10, and YKL40 in HCV
patients with fibrosis (23, 27). In this study, we demonstrate that
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HCV-mediated specific regulation of miRNA-449a and miRNA107 alters expression of CCL2, a major inflammatory chemokine
that is regulated by the IL-6R complex components IL-6R and
JAK1. It is known that CCL2 is expressed in the HSCs, regulates
HSC chemotaxis to the site of injury, and promotes HCV-induced
hepatic fibrosis (28–30). Increased expression of CCL2 is associated with chronic HCV infection, and IFN-␣ therapy has been
shown to reduce its expression (9). Further, inhibition of CCL2
results in reduced cellular infiltration, steatohepatitis, inflammatory responses, and fibrosis during liver injury (31, 32). IL-6 has
also been shown to be upregulated in HCV patients through
NS5A-mediated induction of Toll-like receptor 4 (TLR4) (33),
and IL-6 can induce CCL2, leading to increased inflammatory
responses (34). The results presented in this report indicate that
HCV-induced induction of IL-6 can also lead to induction of
CCL2, resulting in HSC chemotaxis and hepatic fibrosis (Fig. 2).
Transcription factors play a significant role in regulating inflammatory responses, development of fibrosis, and HCC. Our
results demonstrate that CEBP␣, PU.1, and STAT3 form a functional transcriptional-activation complex to regulate CCL2 ex-
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FIG 6 miRNA-449a and miRNA-107 target IL-6R and JAK1 for silencing. Schematic representation of the miRNA-449a (A) and miRNA-107 (E) target sites in
the IL-6R and JAK1 3= UTRs, respectively. (B and F) Hepatocytes were transfected with a luciferase reporter construct containing the IL-6R UTR (B) or the JAK1
UTR (F), along with either a control vector or a vector expressing miRNA-449a or miRNA-107, and luciferase activity was measured. (C, D, G, and H)
Hepatocytes were transfected with an empty vector (⫺) or a vector expressing (⫹) miRNA-449a (C and D) or miRNA-107 (G and H), and expression of IL-6R
(C) and JAK1 (G) was determined by qPCR. The ⌬⌬CT values were calculated by normalizing the CT values with GAPDH and expression of IL-6R and JAK1,
respectively, in controls. *, P ⬍ 0.005; two-tailed t test. IL-6R (D) and JAK1 (H) protein levels in hepatocytes from panels C and G were detected using anti-IL-6R
and anti-JAK1, respectively. Actin is shown as the loading control.

MicroRNA-Mediated Changes in HCV-Induced Inﬂammation

patients, 10 alcoholic-hepatitis patients, 10 NASH patients, and 10 healthy-donor livers (control). Expression levels of IL-6R (A), JAK1 (B), PU.1 (C), STAT3, and
CEBP␣ (E) were determined by qPCR. The ⌬⌬CT values were calculated by normalizing the CT values with GAPDH expression and IL-6R, JAK1, PU.1, STAT3,
and CEBP␣ expression in controls. *, P ⬍ 0.05; two-tailed t test. The error bars represent SD.

pression in hepatocytes (Fig. 3 and 4). CEBP␣ has been shown to
regulate HSC activation, which plays a major role in hepatic fibrosis (35, 36). PU.1 knockout mice lack neutrophils, macrophages,
and mast cells and do not elicit inflammatory responses or fibrosis
(37). Both CEBP␣ and PU.1 bind and cooperate to activate expression of myeloid-specific genes, such as murine neutrophil
elastase promoter and granulocyte colony-stimulating factor (GCSF) receptor, which is necessary for neutrophil differentiation
(38, 39). Further, STAT3 binding to the PU.1 promoter is required
for its expression and subsequent hematological differentiation
(40). STAT3 has also been shown to bind to the promoter and
activate CCL2 expression in rat smooth muscle cells (41). Activated STAT3 is a proviral host factor and is required for HCV
replication (42). Therefore, the CEBP␣-PU.1-STAT3 transcription-regulatory complex plays a significant role in cellular differentiation, inflammatory gene expression, and development of
hepatic fibrosis.
miRNAs are regulators of HCV infection, fibrosis, cirrhosis,
and development of HCC following liver transplantation (21, 43).
miRNAs regulate cytokine signaling on HSCs and expression of
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inflammatory cytokines and interferons, leading to fibrosis (44,
45). We have shown that miRNA-449a and miRNA-107 are specifically downregulated in HCV patients (Fig. 1A and B) and that
miRNA-449a regulates expression of the inflammatory cytokine
YKL40 through components of the NOTCH signaling pathway
(23). miRNA-125b and miRNA-124, which are downregulated in
hepatocarcinoma patients, target IL-6R to modulate the IL-6/
STAT3 pathway and IL-6 production and induce tumorigenicity
(46–48). We demonstrate that expression of miRNA targets IL-6R
and JAK1 and that transcription factors PU.1 and STAT3 are upregulated specifically in HCV patients compared to non-HCV
patients and healthy individuals (Fig. 7). Although STAT3 was
upregulated in alcoholic-hepatitis and NASH patients compared
to healthy donors, the expression was 2-fold higher in HCV patients. We propose that in cases of HCV infection, the viral protein
NS5A or the core protein may increase its expression and promote
phosphorylation and nuclear translocation of STAT3 (49, 50).
Therefore, HCV-induced downregulation of miRNA-449a and
miRNA-107 in human livers can activate transcriptional-regulatory complexes (CEBP␣-PU.1-STAT3) through modulation of
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FIG 7 IL-6R, JAK1, PU.1, and STAT3 are upregulated in HCV patients. Total RNA was isolated from liver biopsy specimens obtained from 10 chronic-HCV
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4.

5.

7.

8.

FIG 8 Schematic representation of HCV-mediated modulation of miRNA449a and miRNA-107 leading to CCL2 expression. HCV infection results in
downregulation of miRNA-449a and miRNA-107, which leads to upregulation of IL-6 receptor complex components IL-6R and JAK1. This results in
increased IL-6-mediated activation and nuclear translocation of phosphorylated STAT3. Activated STAT3, in cooperation with PU.1 and CEBP␣, regulates CCL2 expression through DNA binding.

9.
10.

11.

cell surface receptor (IL-6R/JAK1) expression, thereby promoting
inflammatory responses that lead to development of fibrosis and
HCC (Fig. 8). Since we and others have found that CCL2 is also
elevated in patients with alcoholic hepatitis and NASH (Fig. 1C)
(7–9), although significantly lower than in HCV infection, it is
possible that parallel gene-regulatory mechanisms may operate in
non-HCV-mediated liver diseases.
Taken together, the results of this study provide novel insights
into the miRNA-mediated gene regulation mechanisms that play
a role in HCV-mediated inflammatory responses and development of liver fibrosis. The HCV-specific modulation of miRNA,
transcription factors, and cell surface receptors identified in this
report can be utilized for the potential development of noninvasive biomarkers that can identify HCV patients with higher risk
for developing fibrosis, cirrhosis, and HCC, as well as in developing methods for altering miRNA expression levels (miRNA mimics or antagomirs) as a therapeutic strategy.
ACKNOWLEDGMENTS
This work was supported by NIH DK065982 and the Barnes-Jewish Foundation (T.M.).
We thank Billie Glasscock for her help in preparing the manuscript.
We have no financial conflicts of interest.

REFERENCES
1. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F,
Moyer LA, Kaslow RA, Margolis HS. 1999. The prevalence of hepatitis C
virus infection in the United States, 1988 through 1994. N. Engl. J. Med.
341:556 –562. http://dx.doi.org/10.1056/NEJM199908193410802.
2. Seeff LB. 2002. Natural history of chronic hepatitis C. Hepatology 36:S35–
S46. http://dx.doi.org/10.1053/jhep.2002.36806.
3. Carr MW, Roth SJ, Luther E, Rose SS, Springer TA. 1994. Monocyte
chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc.

3742

jvi.asm.org

12.
13.
14.
15.

16.
17.

18.

19.
20.
21.

22.

Journal of Virology

Downloaded from http://jvi.asm.org/ on April 21, 2014 by Washington University in St. Louis

6.

Natl. Acad. Sci. U. S. A. 91:3652–3656. http://dx.doi.org/10.1073/pnas.91
.9.3652.
Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami
F, Gerrity R, Schwartz CJ, Fogelman AM. 1990. Minimally modified low
density lipoprotein induces monocyte chemotactic protein 1 in human
endothelial cells and smooth muscle cells. Proc. Natl. Acad. Sci. U. S. A.
87:5134 –5138. http://dx.doi.org/10.1073/pnas.87.13.5134.
Standiford TJ, Kunkel SL, Phan SH, Rollins BJ, Strieter RM. 1991.
Alveolar macrophage-derived cytokines induce monocyte chemoattractant protein-1 expression from human pulmonary type II-like epithelial
cells. J. Biol. Chem. 266:9912–9918.
Xu LL, Warren MK, Rose WL, Gong W, Wang JM. 1996. Human
recombinant monocyte chemotactic protein and other C-C chemokines
bind and induce directional migration of dendritic cells in vitro. J. Leukoc.
Biol. 60:365–371.
Bertola A, Bonnafous S, Anty R, Patouraux S, Saint-Paul MC, Iannelli A,
Gugenheim J, Barr J, Mato JM, Le Marchand-Brustel Y, Tran A, Gual P. 2010.
Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients. PLoS One 5:e13577.
http://dx.doi.org/10.1371/journal.pone.0013577.
Degre D, Lemmers A, Gustot T, Ouziel R, Trepo E, Demetter P, Verset
L, Quertinmont E, Vercruysse V, Le Moine O, Deviere J, Moreno C.
2012. Hepatic expression of CCL2 in alcoholic liver disease is associated
with disease severity and neutrophil infiltrates. Clin. Exp. Immunol. 169:
302–310. http://dx.doi.org/10.1111/j.1365-2249.2012.04609.x.
Narumi S, Tominaga Y, Tamaru M, Shimai S, Okumura H, Nishioji K,
Itoh Y, Okanoue T. 1997. Expression of IFN-inducible protein-10 in
chronic hepatitis. J. Immunol. 158:5536 –5544.
Zhang C, Li Y, Wu Y, Wang L, Wang X, Du J. 2013. Interleukin-6/signal
transducer and activator of transcription 3 (STAT3) pathway is essential
for macrophage infiltration and myoblast proliferation during muscle regeneration. J. Biol. Chem. 288:1489 –1499. http://dx.doi.org/10.1074/jbc
.M112.419788.
Hibi M, Murakami M, Saito M, Hirano T, Taga T, Kishimoto T. 1990.
Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell
63:1149 –1157. http://dx.doi.org/10.1016/0092-8674(90)90411-7.
Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. 1998.
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J. 334:297–314.
Huang S. 2007. Regulation of metastases by signal transducer and activator of
transcription 3 signaling pathway: clinical implications. Clin. Cancer Res. 13:
1362–1366. http://dx.doi.org/10.1158/1078-0432.CCR-06-2313.
Scott EW, Simon MC, Anastasi J, Singh H. 1994. Requirement of transcription
factor PU.1 in the development of multiple hematopoietic lineages. Science 265:
1573–1577. http://dx.doi.org/10.1126/science.8079170.
Kim HG, de Guzman CG, Swindle CS, Cotta CV, Gartland L, Scott EW,
Klug CA. 2004. The ETS family transcription factor PU.1 is necessary for
the maintenance of fetal liver hematopoietic stem cells. Blood 104:3894 –
3900. http://dx.doi.org/10.1182/blood-2002-08-2425.
Johnson PF. 2005. Molecular stop signs: regulation of cell-cycle arrest by
C/EBP transcription factors. J. Cell Sci. 118:2545–2555. http://dx.doi.org
/10.1242/jcs.02459.
Lu GD, Leung CH, Yan B, Tan CM, Low SY, Aung MO, Salto-Tellez M,
Lim SG, Hooi SC. 2010. C/EBPalpha is up-regulated in a subset of hepatocellular carcinomas and plays a role in cell growth and proliferation.
Gastroenterology 139:632– 643. http://dx.doi.org/10.1053/j.gastro.2010
.03.051.
Zeng C, Wang R, Li D, Lin XJ, Wei QK, Yuan Y, Wang Q, Chen W, Zhuang
SM. 2010. A novel GSK-3 beta-C/EBP alpha-miR-122-insulin-like growth factor
1 receptor regulatory circuitry in human hepatocellular carcinoma. Hepatology
52:1702–1712. http://dx.doi.org/10.1002/hep.23875.
Gracias DT, Katsikis PD. 2011. MicroRNAs: key components of immune
regulation. Adv. Exp. Med. Biol. 780:15–26. http://dx.doi.org/10.1007
/978-1-4419-5632-3_2.
McManus MT. 2003. MicroRNAs and cancer. Semin. Cancer Biol. 13:
253–258. http://dx.doi.org/10.1016/S1044-579X(03)00038-5.
Sarma NJ, Tiriveedhi V, Ramachandran S, Crippin J, Chapman W,
Mohanakumar T. 2012. Modulation of immune responses following solid
organ transplantation by microRNA. Exp. Mol. Pathol. 93:378 –385. http:
//dx.doi.org/10.1016/j.yexmp.2012.09.020.
Girard M, Jacquemin E, Munnich A, Lyonnet S, Henrion-Caude A.
2008. miR-122, a paradigm for the role of microRNAs in the liver. J.
Hepatol. 48:648 – 656. http://dx.doi.org/10.1016/j.jhep.2008.01.019.

MicroRNA-Mediated Changes in HCV-Induced Inﬂammation

April 2014 Volume 88 Number 7

37.

38.
39.
40.

41.

42.

43.
44.

45.
46.

47.

48.

49.

50.

Chen Q, Li QQ, Xu ZD, Liu XP. 2012. C/EBP-alpha ameliorates CCl(4)induced liver fibrosis in mice through promoting apoptosis of hepatic
stellate cells with little apoptotic effect on hepatocytes in vitro and in vivo.
Apoptosis 17:492–502. http://dx.doi.org/10.1007/s10495-012-0700-y.
Martin P, D’Souza D, Martin J, Grose R, Cooper L, Maki R, McKercher
SR. 2003. Wound healing in the PU.1 null mouse: tissue repair is not
dependent on inflammatory cells. Curr. Biol. 13:1122–1128. http://dx.doi
.org/10.1016/S0960-9822(03)00396-8.
Oelgeschlager M, Nuchprayoon I, Luscher B, Friedman AD. 1996.
C/EBP, c-Myb, and PU.1 cooperate to regulate the neutrophil elastase
promoter. Mol. Cell. Biol. 16:4717– 4725.
Smith LT, Hohaus S, Gonzalez DA, Dziennis SE, Tenen DG. 1996. PU.1
(Spi-1) and C/EBP alpha regulate the granulocyte colony-stimulating factor receptor promoter in myeloid cells. Blood 88:1234 –1247.
Hegde S, Ni S, He S, Yoon D, Feng GS, Watowich SS, Paulson RF,
Hankey PA. 2009. Stat3 promotes the development of erythroleukemia by
inducing Pu.1 expression and inhibiting erythroid differentiation. Oncogene 28:3349 –3359. http://dx.doi.org/10.1038/onc.2009.202.
Potula HS, Wang D, Quyen DV, Singh NK, Kundumani-Sridharan V,
Karpurapu M, Park EA, Glasgow WC, Rao GN. 2009. Src-dependent
STAT-3-mediated expression of monocyte chemoattractant protein-1 is
required for 15(S)-hydroxyeicosatetraenoic acid-induced vascular
smooth muscle cell migration. J. Biol. Chem. 284:31142–31155. http://dx
.doi.org/10.1074/jbc.M109.012526.
McCartney EM, Helbig KJ, Narayana SK, Eyre NS, Aloia AL, Beard MR.
22 May 2013. Signal transducer and activator of transcription 3 (STAT3) is
a pro-viral host factor for hepatitis C virus. Hepatology http://dx.doi.org
/10.1002/hep.26496.
He Y, Huang C, Zhang SP, Sun X, Long XR, Li J. 2012. The potential of
microRNAs in liver fibrosis. Cell Signal. 24:2268 –2272. http://dx.doi.org
/10.1016/j.cellsig.2012.07.023.
He Y, Huang C, Sun X, Long XR, Lv XW, Li J. 2012. MicroRNA-146a
modulates TGF-beta1-induced hepatic stellate cell proliferation by targeting SMAD4. Cell Signal. 24:1923–1930. http://dx.doi.org/10.1016/j.cellsig
.2012.06.003.
McCoy CE. 2012. The role of miRNAs in cytokine signaling. Front. Biosci.
17:2161–2171.
Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I, Inazawa J. 2010.
miR-124 and miR-203 are epigenetically silenced tumor-suppressive
microRNAs in hepatocellular carcinoma. Carcinogenesis 31:766 –776.
http://dx.doi.org/10.1093/carcin/bgp250.
Hatziapostolou M, Polytarchou C, Aggelidou E, Drakaki A, Poultsides
GA, Jaeger SA, Ogata H, Karin M, Struhl K, Hadzopoulou-Cladaras M,
Iliopoulos D. 2011. An HNF4alpha-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell 147:1233–1247. http://dx
.doi.org/10.1016/j.cell.2011.10.043.
Jia HY, Wang YX, Yan WT, Li HY, Tian YZ, Wang SM, Zhao HL. 2012.
MicroRNA-125b functions as a tumor suppressor in hepatocellular carcinoma cells. Int. J. Mol. Sci. 13:8762– 8774. http://dx.doi.org/10.3390
/ijms13078762.
Gong G, Waris G, Tanveer R, Siddiqui A. 2001. Human hepatitis C virus
NS5A protein alters intracellular calcium levels, induces oxidative stress,
and activates STAT-3 and NF-kappa B. Proc. Natl. Acad. Sci. U. S. A.
98:9599 –9604. http://dx.doi.org/10.1073/pnas.171311298.
Yoshida T, Hanada T, Tokuhisa T, Kosai K, Sata M, Kohara M,
Yoshimura A. 2002. Activation of STAT3 by the hepatitis C virus core
protein leads to cellular transformation. J. Exp. Med. 196:641– 653. http:
//dx.doi.org/10.1084/jem.20012127.

jvi.asm.org 3743

Downloaded from http://jvi.asm.org/ on April 21, 2014 by Washington University in St. Louis

23. Sarma NJ, Tiriveedhi V, Subramanian V, Shenoy S, Crippin JS, Chapman WC, Mohanakumar T. 2012. Hepatitis C virus mediated changes in
miRNA-449a modulates inflammatory biomarker YKL40 through components of the NOTCH signaling pathway. PLoS One 7:e50826. http://dx
.doi.org/10.1371/journal.pone.0050826.
24. Sarma NJ, Yaseen NR. 2011. Amino-terminal enhancer of split (AES)
interacts with the oncoprotein NUP98-HOXA9 and enhances its transforming ability. J. Biol. Chem. 286:38989 –39001. http://dx.doi.org/10
.1074/jbc.M111.297952.
25. Ramachandran S, Ilias Basha H, Sarma NJ, Lin Y, Crippin JS, Chapman WC,
Mohanakumar T. 2013. Hepatitis C virus induced miR200c down modulates
FAP-1, a negative regulator of Src signaling and promotes hepatic fibrosis. PLoS
One 8:e70744. http://dx.doi.org/10.1371/journal.pone.0070744.
26. Nishitsuji H, Funami K, Shimizu Y, Ujino S, Sugiyama K, Seya T,
Takaku H, Shimotohno K. 2013. HCV infection induces inflammatory
cytokines and chemokines mediated by the cross-talk between hepatocytes and stellate cells. J. Virol. http://dx.doi.org/10.1128/JVI.00974-13.
27. Basha HI, Subramanian V, Seetharam A, Nath DS, Ramachandran S,
Anderson CD, Shenoy S, Chapman WC, Crippin JS, Mohanakumar T.
2011. Characterization of HCV-specific CD4⫹Th17 immunity in recurrent hepatitis C-induced liver allograft fibrosis. Am. J. Transplant. 11:775–
785. http://dx.doi.org/10.1111/j.1600-6143.2011.03458.x.
28. Marra F, Romanelli RG, Giannini C, Failli P, Pastacaldi S, Arrighi MC,
Pinzani M, Laffi G, Montalto P, Gentilini P. 1999. Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells.
Hepatology 29:140 –148. http://dx.doi.org/10.1002/hep.510290107.
29. Muhlbauer M, Bosserhoff AK, Hartmann A, Thasler WE, Weiss TS,
Herfarth H, Lock G, Scholmerich J, Hellerbrand C. 2003. A novel
MCP-1 gene polymorphism is associated with hepatic MCP-1 expression
and severity of HCV-related liver disease. Gastroenterology 125:1085–
1093. http://dx.doi.org/10.1016/S0016-5085(03)01213-7.
30. Seki E, de Minicis S, Inokuchi S, Taura K, Miyai K, van Rooijen N,
Schwabe RF, Brenner DA. 2009. CCR2 promotes hepatic fibrosis in mice.
Hepatology 50:185–197. http://dx.doi.org/10.1002/hep.22952.
31. Baeck C, Wehr A, Karlmark KR, Heymann F, Vucur M, Gassler N, Huss S,
Klussmann S, Eulberg D, Luedde T, Trautwein C, Tacke F. 2012. Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage
infiltration and steatohepatitis in chronic hepatic injury. Gut 61:416–426. http:
//dx.doi.org/10.1136/gutjnl-2011-300304.
32. Galastri S, Zamara E, Milani S, Novo E, Provenzano A, Delogu W,
Vizzutti F, Sutti S, Locatelli I, Navari N, Vivoli E, Caligiuri A, Pinzani
M, Albano E, Parola M, Marra F. 2012. Lack of CC chemokine ligand 2
differentially affects inflammation and fibrosis according to the genetic
background in a murine model of steatohepatitis. Clin. Sci. 123:459 – 471.
http://dx.doi.org/10.1042/CS20110515.
33. Machida K, Cheng KT, Sung VM, Levine AM, Foung S, Lai MM. 2006.
Hepatitis C virus induces Toll-like receptor 4 expression, leading to enhanced production of beta interferon and interleukin-6. J. Virol. 80:866 –
874. http://dx.doi.org/10.1128/JVI.80.2.866-874.2006.
34. Biswas P, Delfanti F, Bernasconi S, Mengozzi M, Cota M, Polentarutti
N, Mantovani A, Lazzarin A, Sozzani S, Poli G. 1998. Interleukin-6
induces monocyte chemotactic protein-1 in peripheral blood mononuclear cells and in the U937 cell line. Blood 91:258 –265.
35. Huang J, Zhang JS, Huang GC, Tang QQ, Chen C, Zhang XR, Chen Q.
2004. Expression of CCAAT/enhancer-binding protein in cultured rat hepatic stellate cells and its significance. Zhonghua Gan Zang Bing Za Zhi
12:259 –262.
36. Tao LL, Cheng YY, Ding D, Mei S, Xu JW, Yu J, Ou-Yang Q, Deng L,

